
==== Front
J Microbiol Biotechnol
J Microbiol Biotechnol
Journal of Microbiology and Biotechnology
1017-7825
1738-8872
The Korean Society for Microbiology and Biotechnology

39049484
10.4014/jmb.2405.05036
jmb-34-8-1711
Research article
Biotechnology and Bioengineering (BB)
Cell Culture and Biomedical Engineering
Harnessing Decellularized Extracellular Matrix for Enhanced Fidelity in Colorectal Cancer Organoid and Cell-Derived Xenograft Models
Nam Yena 1
Cha Eunju 1
Kwak Su Min 2
Seo Seung Ju 1
Rim John Hoon 3
Jin Yoonhee 12*
1 Department of Physiology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
2 Department of Medicine, College of Medicine, Yonsei University Graduate School, Seoul 03722, Republic of Korea
3 Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
* Corresponding author Phone: +82-2-2228-1714 E-mail: yoonheejin@yuhs.ac
28 8 2024
27 6 2024
27 6 2024
34 8 17111717
30 5 2024
11 6 2024
14 6 2024
Copyright © 2024 by the authors. Licensee KMB
2024
https://creativecommons.org/licenses/by/4.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license
This study evaluates the efficacy of a decellularized intestine tissue-derived extracellular matrix (Intestine ECM) as a scaffold for culturing colorectal cancer (CRC) organoids and establishing cell-derived xenograft (CDX) models, comparing its performance to traditional Matrigel. Intestine ECM demonstrates comparable support for organoid formation and cellular function, highlighting its potential as a more physiologically relevant and reproducible platform. Our findings suggest that Intestine ECM enhances the mimetic environment for colon epithelium, supporting comparable growth and improved differentiation compared to Matrigel. Moreover, when used as a delivery carrier, Intestine ECM significantly increases the growth rate of CDX models using patient-derived primary colorectal cancer cells. This enhancement demonstrates Intestine ECM’s role not only as a scaffold but also as a vital component of the tumor microenvironment, facilitating more robust tumorigenesis. These findings advocate for the broader application of Intestine ECM in cancer model systems, potentially leading to more accurate preclinical evaluations and the development of targeted cancer therapies.

Patient-derived tumor organoid
colorectal cancer
extracellular matrix
xenograft models
==== Body
pmcIntroduction

The advent of organoid technology has marked a significant shift in biological and biomedical research, enabling the in vitro recapitulation of complex, organ-specific architectures, and functions from simple two-dimensional (2D) cell cultures [1, 2]. Organoids, three-dimensional (3D) constructs that mimic miniature organs, have become pivotal in studying organ development, disease mechanisms, and applications in drug discovery and regenerative medicine. Among these, patient-derived tumor organoids (PDOs) represent a substantial advancement, bridging the gap between traditional immortalized cell lines and patient-derived xenograft (PDX) models [3-5]. Notably, PDOs preserve the histological features, gene expression profiles, and drug responses of the donor tumors, establishing them as reliable models for preclinical evaluations of anticancer agents and personalized cancer therapies [6-8].

Organoids require precise cultivation under defined conditions, including specific growth factors and a supportive scaffold, to self-organize into structures that closely mimic their in vivo counterparts [9-11]. This fidelity is vital for cancer research, where replicating patient-specific tumor characteristics and heterogeneity is crucial [12-14]. Traditionally, Matrigel, a hydrogel derived from the Engelbreth-Holm-Swarm mouse sarcoma, has been the standard scaffold for organoid culture. Although its composition mirrors that of the natural extracellular matrix (ECM), containing essential proteins like laminin, collagen IV, entactin, and heparan sulfate proteoglycans necessary for 3D growth, its non-tissue-specific origin presents significant limitations [15,16]. This is particularly critical in colorectal cancer, where the ECM is extensively remodeled and disorganized, playing a pivotal role in influencing key cancer hallmarks such as differentiation, proliferation, angiogenesis, invasion, and metastasis [17-19].

In response to these challenges, tissue decellularization processes have given rise to promising alternatives [20, 21]. These decellularized tissue-derived ECMs (dECMs) preserve a complex array of ECM proteins, growth factors, and other bioactive molecules inherent to the source organ [22, 23]. Commercially available as Regenix® Intestine, derived from porcine intestine, is one such dECM, facilitating an organ-specific microenvironment that supports more effective organoid growth and differentiation than synthetic alternatives [25]. This study utilizes decellularized intestine tissue-derived extracellular matrix (Intestine ECM), to explore its potential as a scaffold for cultivating human colorectal cancer (CRC) organoids and establishing patient cell-derived xenograft (CDX) mouse models. By leveraging this specific ECM, the research aims to enhance the physiological relevance and reproducibility of our models, potentially improving our understanding of disease mechanisms and aiding in developing more effective therapeutic interventions.

Materials and Methods

Cell Culture

This study, involving human colon cancer cells and CRC organoids isolated from patients, was approved by the Institutional Review Board (IRB) of Yonsei University Health System (Permit Number: 4-2023-1545). The CRC organoids (#SNU4351S4-4-TO, #SNU4646S1-TO) were sourced from the Korean Cell Line Bank (Republic of Korea). For CRC organoid culture, the medium consisted of Advanced DMEM/F12 (Dulbecco’s Modified Eagle Medium/HAM’s F-12; #12634-010, Thermo Fisher Scientific, USA) supplemented with 10 mM HEPES (#15630-080, Thermo Fisher Scientific), 2 mM Glutamax (#35050061, Thermo Fisher Scientific), 1% (v/v) penicillin-streptomycin (P/S; #15140122, Thermo Fisher Scientific), 1 mM N-acetyl cysteine (#A9165, Sigma-Aldrich, USA), 0.5 μM A83-01 (#2393, Tocris Bioscience, UK), 1 × B27 (#17504044, Thermo Fisher Scientific), 10 μM SB202190 (#S7067, Sigma-Aldrich), 10 nM gastrin I (#G9145, Sigma- Aldrich), and 50 ng/ml Epidermal Growth Factor (EGF) (#AF-100-15, Peprotech, USA). 10 μM Y-27632 (#1293823, Biogems International, Inc., USA) was added to the medium during the first 1-2 days following passaging. For passaging CRC organoids, Matrigel (#354230, Corning, USA) was degraded using Cell Recovery Solution (#354253, Corning) at 4°C for one hour. For passaging organoids cultured in Intestine ECM hydrogel (#Regenix Intestine, Cellartgen, Korea)—a commercially available decellularized extracellular matrix derived from porcine intestine—were degraded with 2 mg/ml collagenase IV (#17104019, Thermo Fisher) at 37°C for one hour. The colon cancer cell line, SNU-C2B (Korean Cell Line Bank), was cultured in Roswell Park Memorial Institute (RPMI)-1640 medium (#11875093, Thermo Fisher Scientific), supplemented with 10% heat-inactivated fetal bovine serum (#26140079, Thermo Fisher Scientific), 1% (v/v) P/S, and 25 mM HEPES.

Immunofluorescence Staining

Immunofluorescence staining was performed on CRC organoids cultured for 7 days. Initially, Matrigel and Intestine ECM hydrogels were degraded using either Cell Recovery Solution or 2 mg/ml collagenase IV, respectively. The organoids were then fixed in 4% paraformaldehyde (Sigma-Aldrich) for one hour, permeabilized with 0.2% Triton X-100 (Sigma-Aldrich) for 30 min and blocked in 5% bovine serum albumin for 2 h at room temperature (RT). Subsequently, organoids were incubated with primary antibodies, including rabbit anti-Ki67 (#ab15580, 1:1000, Abcam, UK), rabbit anti-mucin 2 (MUC2; #sc-15334, 1:200, Santa Cruz Biotechnology, USA), mouse-anti-E-cadherin (#610181, BD Bioscience, USA) for 24 h at 4°C. After washing three times with phosphate-buffered saline (PBS), the organoids were exposed to secondary antibodies conjugated with goat anti-rabbit Alexa-Fluor 594 (#A-11012, 1:200, Thermo Fischer Scientific), or goat anti-mouse IgG Alexa-Fluor 488 (#A-11008, 1:200, Thermo Fischer Scientific) for another 24 h at 4°C. Filamentous-actin (F-actin) staining was performed with Phalloidin-iFluor 488 Reagent (#ab176753, 1:1000, Abcam) for 24 h at 4°C. After multiple washes with PBS, nuclei were stained with 2-(4-amidinophenyl)-6-indolecarboxamidine dihydrochloride (DAPI, TCI, Japan) for 30 min at RT. The immunostained organoids were visualized using a LSM 980 confocal microscope (Carl Zeiss, Germany).

Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR)

The mRNA expression profiles of CRC organoids were assessed using qPCR. mRNA samples were extracted from organoids cultured for 9 days using the TaKaRa miniBEST Universal RNA Extraction Kit (TaKaRa, Japan). cDNA was then synthesized from the isolated mRNA using a cDNA synthesis kit (TaKaRa). qPCR was performed using the TaqMan Fast Universal Master Mix system (Applied Biosystems, USA) on a QuantStudio 3 Real-Time PCR system (Applied Biosystems). Primers targeting leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5; Hs00969422_m1), Ki67 (MKI67; Hs04260396_g1), mucin 2 (MUC2; Hs03005103_g1), and villin (VILL; Hs00210626_m1) were used. Relative gene expression levels were quantified using the cycle threshold (Ct) method, with glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Hs02786624_g1) serving as the reference gene.

Forskolin-Induced Swelling Assay

Forskolin-induced swelling assays were conducted on CRC organoids to assess the regulation of luminal fluid secretion [24, 25]. Organoids cultured in either Intestine ECM or Matrigel were incubated in culture medium supplemented with 10 μM forskolin. The organoid size was measured every 20 min using an EVOS M5000 microscope (Thermo Fisher Scientific). Area analysis of the organoids was conducted using ImageJ software (National Institutes of Health, USA).

Animals and Ethics Statements

For in vivo studies, the procedures were approved by the Institutional Animal Care and Use Committee of Yonsei University College of Medicine under permit number 2024-0106. All experiments involving animals were conducted in facilities accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International). The animals were maintained under controlled environmental conditions with a temperature of 21 ± 2°C, humidity of 50 ± 10%, ventilation of 10-15 air changes per hour, and noise levels maintained below 60 dB.

Generation of CDX Models

Colon cancer cells (#SNU-C2B) were used for engraftment into 6-week-old BALB/c nude male mice (Orientbio, Republic of Korea). The nude mouse was anesthetized with 2% inhaled isoflurane. Each mouse received a subcutaneous injection of 1 × 106 cells in a 100 μl Intestine ECM (#Regenix Intestine) into the right flank. For the control group, cells resuspended in 100 μl PBS was injected.

Results

Characterization of CRC Organoids Cultured in Intestine ECM

In assessing the effectiveness of the Intestine ECM for CRC organoid cultures, we compared it directly to the traditionally used Matrigel. Our findings revealed that organoid formation efficiency was comparably high with both Intestine ECM and Matrigel (Fig. 1A and 1B), demonstrating that the biophysical and biochemical properties of Intestine ECM are adequate for supporting the growth and maintenance of CRC organoids.

Immunostaining revealed that the intestinal epithelial marker (ECAD), the proliferation marker (Ki67), and the goblet cell marker (MUC2) crucial for the colonic mucus barrier [26, 27], exhibited similar expression levels in organoids cultured in both Intestine ECM and Matrigel (Fig. 1C). This similarity indicates the presence of actively dividing cells and suggests that Intestine ECM supports cellular proliferation effectively. Furthermore, no significant differences were observed in the number of focal adhesions or the organization of the cytoskeleton between the two scaffolds, indicating that Intestine ECM maintains cell-matrix interactions comparable to those of Matrigel (Fig. 1C).

Further investigation was carried out through qRT-PCR analysis (Fig. 1D). The analysis revealed that the stemness marker LGR5 in CRC organoids expressed at comparable levels in both scaffolds, confirming that Intestine ECM supports stem cell populations effectively. Importantly, differentiation markers such as MUC2 and VILL, an enterocyte marker gene [28, 29], showed significantly higher expression in organoids cultured in Intestine ECM. This increase in differentiation marker expression suggests that Intestine ECM provides an enhanced mimetic environment for colon epithelial biology compared to Matrigel. Additionally, the proto-oncogene MYC, known to be associated with cancer progression [30-32], was also elevated in the Intestine ECM scaffold, further indicating the scaffold's potential to support enhanced intestinal gene expression.

Consistency across Different Batches of Intestine ECM

Given the natural origin of dECM products, concerns about batch-to-batch variability are significant. Addressing this, CRC organoids were cultured using Intestine ECM sourced from different production lots (Fig. 2). The findings revealed consistent organoid formation efficiencies across two distinct batches of Intestine ECM (Fig. 2A and 2B). Additionally, similar expression levels of proliferation and intestinal markers, including LGR5, MKI67, MUC2, and VILL were observed (Fig. 2C). This consistency in performance indicates the reliability of Intestine ECM as a scaffold and suggests that, despite its derivation from natural sources, Intestine ECM maintains stable quality across different production lots.

Functional Assessment of CFTR in CRC Organoids Cultured in Intestine ECM

Next, the function of the cystic fibrosis transmembrane conductance regulator (CFTR) in CRC organoids cultured in Intestine ECM hydrogel was compared with those cultured in Matrigel, utilizing a forskolin-induced swelling assay (Fig. 3). Both groups of CRC organoids exhibited rapid growth at similar rates following forskolin treatment, indicating that organoids cultivated in Intestine ECM hydrogel maintain their ability to regulate luminal fluid secretion (Fig. 3A and 3B). These results validate the effectiveness of Intestine ECM hydrogels as platforms for PDO culture, supporting the generation and differentiation of CRC organoids with structural and functional characteristics comparable to those grown in Matrigel.

Generation of Xenograft Models Using Intestine ECM

To assess the efficacy of Intestine ECM in supporting tumor formation, we utilized primary patient-derived colorectal cancer cells, which were injected into immunodeficient mice to form xenograft models (Fig. 4). Over a period of four weeks, cells injected with Intestine ECM demonstrated a significantly faster rate of tumor formation compared to the control where only cells were injected (Fig. 4A). Tumors formed with Intestine ECM were significantly larger in volume, indicating enhanced tumorigenic potential (Fig. 4A-4C). Histological examination using hematoxylin and eosin (H&E) staining revealed similar morphological characteristics between the two groups (Fig. 4D).

Discussion

This study has successfully demonstrated the effectiveness of Intestine ECM as a scaffold for CRC organoids and establishing CDX models. By showing that Intestine ECM supports organoid formation and cellular functions as competently as Matrigel, this study makes a significant contribution to the field of oncology research. Intestine ECM provides a more physiologically relevant and reproducible platform, which is crucial for improving the accuracy of preclinical models in predicting clinical outcomes and facilitating the development of personalized medicine approaches.

One of the core advantages of using patient-derived cancer organoids is their ability to maintain the genetic and phenotypic characteristics of the donor's tumor, providing a unique opportunity to tailor chemotherapy options to individual patients. These organoids serve as a vital tool for oncologists, enabling the customization of treatment plans based on the specific cellular behavior exhibited by the organoid model. By integrating Intestine ECM in the cultivation of these organoids, our study leverages this capability to simulate a more accurate tumor microenvironment, enhancing the relevance of our findings to actual clinical scenarios.

The application of PDX models, crucial for preclinical evaluations of anticancer drugs, benefits significantly from advancements in scaffold technologies like Intestine ECM. PDX models, which maintain the histopathological and genetic characteristics of human tumors, serve as essential tools for screening molecular markers and testing drug responses. However, the variability in tumor engraftment efficacy among different cell lines underscores the need for improved methodologies like those provided by Intestine ECM, which has shown potential to accelerate tumor growth and increase tumor volume. By enhancing the engraftment success rate and tumor dynamics, Intestine ECM could substantially improve the utility of PDX models in drug testing and development. Our use of comprehensive and robust methodologies in this study establishes the effectiveness of Intestine ECM in creating accurate and clinically relevant models of colorectal cancer. These models reflect the complex interactions within the tumor microenvironment and offer substantial promise for advancing personalized cancer therapy.

Acknowledgments

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2021R1C1C2009131, No. 2022R1A2C1013380) and the Bio & Medical Technology Development Program of the NRF & funded by the Korean government (MSIT) (No. 2022M3A9B6082675). This work also supported by a grant (20024298) from the Technology Innovation Program funded by the Ministry of Trade, Industry & Energy (MOTIE, Korea).

Fig. 1 CRC organoid cultivation in Intestine ECM demonstrates enhanced differentiation.

(A) Bright-field images showing the progression of CRC organoids from day 0 to day 7 cultured in Intestine ECM and Matrigel (Scale bars = 100 μm and 500 μm), demonstrating organoid growth over time. (B) Quantification of organoid formation efficiency in Intestine ECM compared to Matrigel (n = 10, statistical analysis performed using a two-tailed unpaired t-test). (C) Immunofluorescence staining images for ECAD (intestinal epithelial marker), Ki67 (proliferation marker), Muc2 (goblet cell differentiation marker), and F-actin (cytoskeleton staining) of CRC organoids cultured in Intestine ECM and Matrigel (scale bars = 50 μm), illustrating cellular composition and architecture. (D) Gene expression analysis of key markers between organoids cultured in Intestine ECM and Matrigel (n = 3). Data analyzed using a two-tailed unpaired t-test; significance indicated by *p < 0.05, **p < 0.01, ***p < 0.001 versus Matrigel group, highlighting differences in gene expression levels.

Fig. 2 Consistent performance of Intestine ECM across different batches for culturing CRC organoids.

(A) Bright-field images of CRC organoids cultured in Intestine ECM from different production lots of Intestine ECM after 7 days (scale bars = 500 μm), illustrating the uniformity in organoid growth and morphology. (B) Quantification of organoid formation efficiency in two different batches of Intestine ECM compared to Matrigel (n = 3), illustrating consistent performance across batches. (n = 3). (C) Gene expression analysis comparing two different batches of Intestine ECM (n = 3). Data were analyzed using one-way ANOVA with a Tukey multiple comparison test. No significant differences were found, indicated by N.S. (not significant); **p < 0.01, ***p < 0.001 versus Matrigel group.

Fig. 3 Comparable forskolin-induced swelling in CRC organoids cultured in Intestine ECM.

(A) Bright-field images showing CRC organoids before and 120 min after treatment with 10 μM forskolin, demonstrating the organoids' enlargement (scale bars = 100 μm). (B) Quantification of the rate of enlargement measured at 20-min intervals up to 120 min. The increase in size is significant compared to organoids with no treatment and those treated with a DMSO control (n = 11). Data analyzed using two-way ANOVA with Tukey's multiple comparison test. ***P < 0.001 versus respective DMSO control groups (asterisks in blue for Intestine ECM, in red for Matrigel).

Fig. 4 Efficacy of Intestine ECM in supporting colon cancer CDX model development.

(A) Photographs of the tumor on mice at 28 days post-injection of colon cancer cells with Intestine ECM (scale bar = 5 mm). (B) Images of the tumor after extraction, demonstrating size and morphology (scale bar = 1 cm). (C) Graph showing the growth trajectory of tumors over time, with measurements taken at regular intervals after injection of CRCs mixed with Intestine ECM. This illustrates the progressive increase in tumor size, indicating effective tumor development. (D) Hematoxylin and eosin (H&E) stained images of sectioned tumors (scale bars = 100 μm).

Conflict of Interest

The authors have no financial conflicts of interest to declare.
==== Refs
References

1 Fatehullah A Tan SH Barker N 2016 Organoids as an in vitro model of human development and disease Nat. Cell. Biol. 18 246 254 10.1038/ncb3312 26911908
2 Lancaster MA Knoblich JA 2014 Organogenesis in a dish: modeling development and disease using organoid technologies Science 345 1247125 10.1126/science.1247125 25035496
3 Liu Y Wu W Cai C Zhang H Shen H Han Y 2023 Patient-derived xenograft models in cancer therapy: technologies and applications Signal Transduct. Target. Ther. 8 160 10.1038/s41392-023-01419-2 37045827
4 Cho SY Kang W Han JY Min S Kang J Lee A 2016 An integrative approach to precision cancer medicine using patientderived xenografts Mol. Cells 39 77 86 10.14348/molcells.2016.2350 26831452
5 Jung YH Park K Kim M Oh H Choi DH Ahn J 2023 Development of an extracellular matrix plate for drug screening using patient-derived tumor organoids Biochip. J. 17 284 292 10.1007/s13206-023-00099-y
6 Fujii M Shimokawa M Date S Takano A Matano M Nanki K 2016 A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis Cell Stem Cell 18 827 838 10.1016/j.stem.2016.04.003 27212702
7 Toshimitsu K Takano A Fujii M Togasaki K Matano M Takahashi S 2022 Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer Nat. Chem. Biol. 18 605 614 10.1038/s41589-022-00984-x 35273398
8 Nagle PW Plukker JTM Muijs CT van Luijk P Coppes RP 2018 Patient-derived tumor organoids for prediction of cancer treatment response Semin. Cancer Biol. 53 258 264 10.1016/j.semcancer.2018.06.005 29966678
9 Heo JH Kang D Seo SJ Jin Y 2022 Engineering the extracellular matrix for organoid culture Int. J. Stem Cells 15 60 69 10.15283/ijsc21190 35220292
10 Jung P Sato T Merlos-Suárez A Barriga FM Iglesias M Rossell D 2011 Isolation and in vitro expansion of human colonic stem cells Nat. Med. 17 1225 1227 10.1038/nm.2470 21892181
11 Sensi F D'Angelo E D'Aronco S Molinaro R Agostini M 2018 Preclinical three-dimensional colorectal cancer model: the next generation of in vitro drug efficacy evaluation J. Cell Physiol. 234 181 191 10.1002/jcp.26812 30277557
12 Van De Wetering M Francies HE Francis JM Bounova G Iorio F Pronk A 2015 Prospective derivation of a living organoid biobank of colorectal cancer patients Cell 161 933 945 10.1016/j.cell.2015.03.053 25957691
13 Drost J Clevers H 2018 Organoids in cancer research Nat. Rev. Cancer 18 407 418 10.1038/s41568-018-0007-6 29692415
14 Zeki SS Graham TA Wright NA 2011 Stem cells and their implications for colorectal cancer Nat. Rev. Gastroenterol. Hepatol. 8 90 100 10.1038/nrgastro.2010.211 21293509
15 Kleinman HK Martin GR 2005 Matrigel: basement membrane matrix with biological activity Semin. Cancer Biol. 15 378 386 10.1016/j.semcancer.2005.05.004 15975825
16 Hughes CS Postovit LM Lajoie GA 2010 Matrigel: a complex protein mixture required for optimal growth of cell culture Proteomics 10 1886 1890 10.1002/pmic.200900758 20162561
17 Yuan Z Li Y Zhang S Wang X Dou H Yu X 2023 Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments Mol. Cancer 22 48 10.1186/s12943-023-01744-8 36906534
18 Varinelli L Guaglio M Brich S Zanutto S Belfiore A Zanardi F 2022 Decellularized extracellular matrix as scaffold for cancer organoid cultures of colorectal peritoneal metastases J. Mol. Cell Biol. 14 mjac064 10.1093/jmcb/mjac064 36460033
19 Chen K Xu M Lu F He Y 2023 Development of matrix metalloproteinases-mediated extracellular matrix remodeling in regenerative medicine: a mini review Tissue Eng. Regen. Med. 20 661 670 10.1007/s13770-023-00536-x 37160567
20 Aisenbrey EA Murphy WL 2020 Synthetic alternatives to matrigel Nat. Rev. Mater. 5 539 551 10.1038/s41578-020-0199-8 32953138
21 Kim S Min S Choi YS Jo SH Jung JH Han K 2022 Tissue extracellular matrix hydrogels as alternatives to matrigel for culturing gastrointestinal organoids Nat. Commun. 13 1692 10.1038/s41467-022-29279-4 35354790
22 Lam D Enright HA Cadena J Peters SKG Sales AP Osburn JJ 2019 Tissue-specific extracellular matrix accelerates the formation of neural networks and communities in a neuron-glia co-culture on a multi-electrode array Sci. Rep. 9 4159 10.1038/s41598-019-40128-1 30858401
23 Giobbe GG Crowley C Luni C Campinoti S Khedr M Kretzschmar K 2019 Extracellular matrix hydrogel derived from decellularized tissues enables endodermal organoid culture Nat. Commun. 10 5658 10.1038/s41467-019-13605-4 31827102
24 Boj SF Vonk AM Statia M Su J Vries RRG Beekman JM 2017 Forskolin-induced swelling in intestinal organoids: an in vitro assay for assessing drug response in cystic fibrosis patients J. Vis. Exp. 2017 55159 10.3791/55159 28287550
25 Dekkers JF Wiegerinck CL De Jonge HR Bronsveld I Janssens HM De Winter-De Groot KM 2013 A functional CFTR assay using primary cystic fibrosis intestinal organoids Nat. Med. 19 939 945 10.1038/nm.3201 23727931
26 O'Rourke KP Loizou E Livshits G Schatoff EM Baslan T Manchado E 2017 Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer Nat. Biotechnol. 35 577 582 10.1038/nbt.3837 28459450
27 Fang G Lu H Rodriguez de la Fuente L Law AMK Lin G Jin D 2021 Mammary tumor organoid culture in non-adhesive alginate for luminal mechanics and high-throughput drug screening Adv. Sci. (Weinh) 8 2102418 10.1002/advs.202102418 34494727
28 Bacchi CE Gown AM 1991 Distribution and pattern of expression of villin, a gastrointestinal-associated cytoskeletal protein, in human carcinomas: a study employing paraffin-embedded tissue Lab. Invest. 64 418 424 2002658
29 Arango D Al-Obaidi S Williams DS Dopeso H Mazzolini R Corner G 2012 Villin expression is frequently lost in poorly differentiated colon cancer Am. J. Pathol. 180 1509 1521 10.1016/j.ajpath.2012.01.006 22349300
30 Hsieh AL Walton ZE Altman BJ Stine ZE Dang C V 2015 MYC and metabolism on the path to cancer Semin. Cell Dev. Biol. 43 11 21 10.1016/j.semcdb.2015.08.003 26277543
31 Dang C V 2012 MYC on the path to cancer Cell 149 22 35 10.1016/j.cell.2012.03.003 22464321
32 Dhanasekaran R Deutzmann A Mahauad-Fernandez WD Hansen AS Gouw AM Felsher DW 2022 The MYC oncogene - the grand orchestrator of cancer growth and immune evasion Nat. Rev. Clin. Oncol. 19 23 36 10.1038/s41571-021-00549-2 34508258
33 Cattaneo CM Dijkstra KK Fanchi LF Kelderman S Kaing S van Rooij N 2020 Tumor organoid-T-cell coculture systems Nat. Protoc. 15 15 39 10.1038/s41596-019-0232-9 31853056
34 Dijkstra KK Cattaneo CM Weeber F Chalabi M van de Haar J Fanchi LF 2018 Generation of tumor-reactive T cells by coculture of peripheral blood lymphocytes and tumor organoids Cell 174 1586 1598.e12 10.1016/j.cell.2018.07.009 30100188
